BREAKING NEWS – Split decision in Amgen v. Sandoz

Amgen v. Sandoz (filgrastim)  •  Biosimilar News  •  BPCIA and Related U.S. Statutes

BREAKING NEWS – Split decision in Amgen v. Sandoz – the dance is “optional” but notice of commercial marketing can only be given after approval.  Decision here.  Our summary of oral argument here.  Detailed discussion of today’s decision to follow later today.

Download PDF

Tagged with 

Comments are closed.